logo
Cardinal Health, Inc. (NYSE:CAH) is favoured by institutional owners who hold 89% of the company

Cardinal Health, Inc. (NYSE:CAH) is favoured by institutional owners who hold 89% of the company

Yahoo2 days ago

Institutions' substantial holdings in Cardinal Health implies that they have significant influence over the company's share price
The top 20 shareholders own 51% of the company
Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
A look at the shareholders of Cardinal Health, Inc. (NYSE:CAH) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 89% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.
In the chart below, we zoom in on the different ownership groups of Cardinal Health.
See our latest analysis for Cardinal Health
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
As you can see, institutional investors have a fair amount of stake in Cardinal Health. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Cardinal Health, (below). Of course, keep in mind that there are other factors to consider, too.
Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Cardinal Health. Our data shows that BlackRock, Inc. is the largest shareholder with 13% of shares outstanding. The Vanguard Group, Inc. is the second largest shareholder owning 13% of common stock, and State Street Global Advisors, Inc. holds about 5.5% of the company stock.
After doing some more digging, we found that the top 20 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our data suggests that insiders own under 1% of Cardinal Health, Inc. in their own names. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$140m of stock. Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
With a 10% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Cardinal Health. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Cardinal Health .
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morehead City businesses anticipating spike in sales with Big Rock Tournament approaching
Morehead City businesses anticipating spike in sales with Big Rock Tournament approaching

Yahoo

time17 minutes ago

  • Yahoo

Morehead City businesses anticipating spike in sales with Big Rock Tournament approaching

MOREHEAD CITY, N.C. (WNCT) — With The Big Rock Tournament right around the corner, local businesses in Morehead City are anticipating a spike in sales and customers. Local business owners know the impact Big Rock has on Morehead City and it's importance for showcasing what makes the area so special. 'We really embrace that kind of everybody coming from all over the place just to see the event and experience Morehead City,' Live Eat Surf Shawn Blonk said. 'It really kind of exposes this beautiful area and network and community to the rest of the country. And honestly, the state that hasn't seen it before.' Starting on Wednesday, roads will begin to close in preparation for the start of the tournament, which will begin on June 6th and continue through June 15th. For more information, click on the video above. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

OPSO discusses funding needs for jail repairs with city council
OPSO discusses funding needs for jail repairs with city council

Yahoo

time17 minutes ago

  • Yahoo

OPSO discusses funding needs for jail repairs with city council

NEW ORLEANS (WGNO) — During the special council meeting, Orleans Parish Sheriff Susan Hutson insisted that the Orleans Parish Sheriff's Office is in need of about $1 million to address plumbing concerns in the jail, including $300,000 to $400,000 for emergency repairs to fix immediate leaks behind the walls. According to a plumbing contractor brought in by Hutson, the leaks were slow at first, but a pressure change caused the pipes to burst. New Orleans jail escapee releases videos, prompting search of home where they were made, source says 'Some sort of a pressure increase or whatever blew out the o-ring out in this, and then it just started leaking through the chase and then throughout the entire building,' OPSO plumbing contractor Ernie Anderson said. The city council was hesitant to agree to hand over the money, questioning if the OPSO already has enough funds to cover this problem. At the meeting, Louisiana Legislative Auditor Mike Waguespack said that, after taking a look, Hutson has about $5 million of emergency funds before the city would need to step in. 'Yeah I think they would have plenty of dollars to do any major renovation,' Waguespack said. Councilman JP Morrell questioned the urgency for city money, saying he never received any notice of severe plumbing-related issues before now. Social media video appears to show escaped New Orleans inmate Antoine Massey pleading case 'I still don't have any estimates regarding plumbing issues. I understand emergent plumbing issues, but your words, what you've been saying is these are long standing plumbing issues the council has been aware of,' Morrell said. Hutson ultimately argued against his point, saying she has notified the council every step of the way about plumbing issues since the jail has been open. 'We have notified you every budget cycle, every chance we get up here that we have infrastructure issues and the plumbing been part of them. We didn't have this major leak until recently,' Hutson Orleans police searching for suspect in St. Claude art heist Three arrested in St. John Parish drug bust OPSO discusses funding needs for jail repairs with city council 'Blessing of the Fleet' ceremony held in New Orleans at start of Hurricane Season NORD Splash Day summer kickoff Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Why BioNTech Stock Soared Today
Why BioNTech Stock Soared Today

Yahoo

time33 minutes ago

  • Yahoo

Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase 3 trials, and now Bristol will help to fund further trials. Cash payments to BioNTech could exceed $11 billion over time. 10 stocks we like better than BioNTech Se › BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely unrelated to COVID. The German biotech announced this morning it is partnering with pharmaceuticals giant Bristol Myers Squibb (NYSE: BMY) to "co-develop and co-commercialize" BioNTech's drug candidate BNT327 as an immunotherapy against multiple kinds of cancer. BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is already involved in "multiple" ongoing clinical trials, including an advanced phase 3 trial testing its usefulness in treating breast cancer and both small cell and non-small cell lung cancer. BioNTech CEO Dr. Uğur Şahin expressed the belief that "BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications." Bristol CEO Christopher Boerner agreed that BNT327 has "significant potential for transforming the standard of care for patients with solid tumors." There are more immediate benefits for BioNTech stock, beginning with Bristol Myers Squibb paying BioNTech $1.5 billion up front for the rights to team up and a further $2 billion in noncontingent payments through 2028 as drug development continues. Additional developmental, regulatory, and commercial milestones, which are contingent on successful development, could add a further $7.6 billion to BioNTech's balance sheet over time. With its lucrative COVID days behind it, BioNTech reported nearly $690 million in losses last year and turned free-cash-flow negative. A tidal wave of cash from Bristol Myers Squibb could really come in handy right about now. Before you buy stock in BioNTech Se, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and BioNTech Se wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. Why BioNTech Stock Soared Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store